The short version
- Botox for hyperhidrosis is two administration codes plus the drug: 64650 for chemodenervation of the eccrine glands in the axillae, 64653 for other areas, and J0585 for the onabotulinumtoxinA per unit.
- Coverage requires documented failure of conservative treatment first — typically prescription-strength antiperspirants, and sometimes iontophoresis.
- Bill the J0585 drug code only if your office supplied the drug; if the pharmacy supplied it, the pharmacy bills for it.
- The cumulative dose shouldn’t exceed 600 units in a 90-day period, and CMS restricts which ICD-10 codes support medical necessity. (Those restrictions surface in the Medical Necessity tool on Billing IQ, searchable by code.)
Hyperhidrosis Botox codes: 64650 (axillae) vs 64653 (other areas)
Therapeutic Botox for sweating bills in the same two-part shape as the rest of therapeutic Botox: an administration code plus the drug. The administration splits by site, 64650 is chemodenervation of the eccrine glands in the axillae, 64653 covers other areas such as palms, soles, or craniofacial. J0585 reports the onabotulinumtoxinA per unit. And 64650 already covers both underarms in a single code, so it’s billed once — appending modifier 50 for two sides is a common error, not extra pay.
So the body region picks the administration code, and the units picked the J-code count. This is the sweating indication; the migraine and other therapeutic uses follow the same J0585-plus-administration logic we cover in our therapeutic Botox guide.
The administration codes themselves pay little. Under Medicare’s 2026 schedule, 64650 runs about $87 in the office and $33 in a facility, and 64653 about $102 and $43. The dollars are in the drug: a typical axillary session is roughly 100 units of J0585, ASP-priced, and that’s where buy-and-bill decides whether you actually collect it (below).
These are Medicare national averages at the 2026 conversion factor, and J0585’s ASP changes quarterly — your locality and every commercial contract will differ, so check your own payer grid before you rely on a number.
The failed prescription-antiperspirant gate
The coverage gate is conservative therapy, and it’s specific. Payer policy wants documented failure of prescription-strength antiperspirants before Botox for primary axillary hyperhidrosis is medically necessary, and sometimes a trial of iontophoresis as well.
So the necessity isn’t the sweating itself, it’s the failed cheaper treatment. A clean diagnosis of hyperhidrosis without the documented antiperspirant trial reads as skipping the line, exactly like the failed-preventive requirement on migraine Botox. Document the prescription antiperspirant, the dates, and its failure, then bring the Botox. And the diagnosis has to be one CMS lists as supporting medical necessity, generalized or cosmetic sweating won’t qualify.
Billing J0585 — only if your office supplied it
One quiet rule causes a lot of duplicate-billing headaches: you bill J0585 only if your office supplied the drug. If the drug came from a specialty pharmacy, the pharmacy bills for it, and reporting J0585 anyway double-bills the toxin. Buy-and-bill means you bill the J-code; pharmacy-supplied means you don’t.
And the units have a ceiling: the cumulative dose generally shouldn’t exceed 600 units in a 90-day period. So the drug side of the claim has two disciplines, report J0585 only when you sourced the drug, and keep the 90-day unit total within the cap. Miss either and the line denies or gets recouped.
Documenting hyperhidrosis for coverage
The hyperhidrosis Botox claim that clears carries the qualifying diagnosis (primary focal hyperhidrosis, on the supporting ICD-10 list), the documented failure of prescription antiperspirants, the correct site administration code (64650 or 64653), the J0585 units within the 90-day cap, and the drug-source basis for billing or not billing the J-code, plus prior authorization.
Build the failed-conservative-therapy record before the visit, because that’s the line most denials die on. If hyperhidrosis Botox is denying on the conservative trial or the drug billing, our medical billing operation works the documentation, the units, and the appeals behind them.
Frequently asked questions
Is Botox for hyperhidrosis covered by insurance?
Yes, for primary focal hyperhidrosis when conservative treatment has failed. Botox is billed with CPT 64650 (axillae) or 64653 (other areas) plus J0585 for the drug, and payers require documented failure of prescription-strength antiperspirants (and sometimes iontophoresis) first. Generalized or cosmetic sweating doesn’t qualify.
What CPT codes are used for hyperhidrosis Botox?
64650 reports chemodenervation of the eccrine glands in the axillae; 64653 covers other areas such as palms, soles, or the craniofacial region; and J0585 reports the onabotulinumtoxinA per unit. The treated site determines the administration code and the units determine the J0585 count.
Do you bill modifier 50 for both underarms?
No. CPT 64650 already describes chemodenervation of both axillae in a single code, so it’s reported once per session even though both underarms are treated — appending modifier 50 doesn’t add payment and can trigger a denial. Neither hyperhidrosis administration code carries a bilateral payment adjustment.
What does insurance require before covering hyperhidrosis Botox?
Documented failure of conservative treatment — typically prescription-strength antiperspirants, and sometimes iontophoresis — plus a qualifying diagnosis of primary focal hyperhidrosis on the supporting ICD-10 list, and prior authorization. The failed conservative trial is the most common point of denial.
When do you bill J0585 for hyperhidrosis Botox?
Only when your office supplied the drug (buy-and-bill). If a specialty pharmacy supplied it, the pharmacy bills for the drug, and reporting J0585 would double-bill it. The cumulative dose should also stay within roughly 600 units per 90-day period.
Why was my hyperhidrosis Botox claim denied?
Common reasons are no documented failure of prescription antiperspirants, a diagnosis not on the supporting ICD-10 list, the wrong site code (64650 vs 64653), billing J0585 when the pharmacy supplied the drug, or exceeding the 600-unit/90-day cap.
This article explains how these codes tend to get paid — it is not coding, billing, or legal advice. Some of the codes here are bundled into the main procedure, or fall into grey areas that vary by payer. Before billing anything in a grey area, confirm it with your own coding and compliance team and the current guidance from the American Academy of Dermatology (AAD), Medicare (CMS), and AMA CPT. When in doubt, don’t bill it.
